Search Results - Alyssa Garrelts

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA by Andrew Blauvelt, Alyssa Garrelts, William Malatestinic, Julie Birt, Baojin Zhu, Meghan Feely

Connect to this object online.

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses by Richard B. Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg

Connect to this object online.

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab... by Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H. Chih-Ho Hong, Meghan Feely, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green

Connect to this object online.

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of hea... by Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A. Papp

Connect to this object online.

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks by Alexander Egeberg, Lars Erik Kristensen, Luis Puig, Phoebe Rich, Saxon D. Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster

Connect to this object online.